
MANAGING TRADE SECRETS WHEN YOU KNOW PATENTS


JAMES POOLEY
2018 FICPI WORLD CONGRESS

JUNE 6, 2018

HOW LAWYERS SEE TRADE SECRETS



HOW CLIENTS SEE TRADE SECRETS



TS VS. PATENTS: THE CLASSICAL VIEW

Kewanee: TS are weak; if you can, you'll patent it

The usual factors

Risk of reverse engineering

Period of commercial exploitation

Suitability for licensing

Difficulty of design-around

Critical need to use the invention

Procurement and maintenance costs

Patent as leverage or message

BUT PATENT RIGHTS FEEL DIMINISHED

Judicial opinions on procurement

KSR: obviousness

Bilski: business methods

Mayo: diagnosis

Nautilus: definiteness

Akamai: divided infringement

Alice: software

PATENT RIGHTS FEEL MORE DIMINISHED

Judicial opinions on enforcement

eBay: injunctions

Sandisk: declaratory relief

Laser Dynamics: damaged

Octane Fitness: fee shifting

And then there's the AIA:

PGR and IPR => uncertainty of title Will the pendulum swing back?

MEANWHILE, TRADE SECRETS ARE ASCENDANT

2012 NSF/Census: TS important >2X patents

Defend Trade Secrets Act of 2016

EU Trade Secrets Directive

Bilateral and regional trade agreements

TianRui, 661 F.3d 1322 (Fed. Cir. 2011)

Moore dissent: TS reduces patent disclosure

Note: DTSA extraterritoriality not resolved

AIA ALSO REDUCES TS ANXIETY AND RISK

Prior user anxiety mostly gone

Best mode is virtually dead

But residual anxiety for prosecutors?

Secret prior art is likely dead

So . . . reconsider the cost/benefit analysis

PRACTICAL IMPLICATIONS

The question is not binary, and it's not static

TS are mostly supplemental and complementary

Patents remain valuable and often critical

Not just protection but also signaling

And remember *Kewanee*: TS are weak and risky

Strategy level: rethinking the calculus and balance

Buy time with provisional, maybe U.S. only

Accelerate examination

Tactical: watch NDA partners for leaks, derivative claims

IN THE MEANTIME . . .

TS are about Risk Management

- People: recruiting, training, termination
- Process: policies, access controls, endpoint controls
- Management: NDAs, supply chain, litigation avoidance



"But how could me speaking at the Secret New Products Seminar break our Confidentiality Agreement?"

Thank you!

JAMES POOLEY

www.pooley.com

+1 650 285 8520